Prof. Dalin Li 李大林
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast-conserving surgery, sentinel lymph node biopsy, modified radical mastectomy, neoadjuvant and adjuvant systemic therapy, immediate breast reconstruction, Mammotome minimally invasive surgery, and endoscopic mastectomy with implant reconstruction.
Dr. Li earned a medical degree from Harbin Medical University in 1999, a master’s in anatomy and histology in 2008, and a doctorate in oncology in 2014, followed by postdoctoral training. Dr. Li joined Harbin Medical University Cancer Hospital in 1999, advancing to chief physician and professor. Training included a fellowship at MD Anderson Cancer Center (2013) and laboratory research at Texas A&M Health Science Center.
Professional roles
- Member, Heilongjiang Anti-Cancer Association
- Standing Committee Member, Harbin Plastic Surgery Committee
Name order: in Chinese the family name comes first (Li Dalin). Papers usually list the name as Dalin Li or Li D.
Selected publications
18 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Discov Oncol, 2026 (senior author): Integrating single-cell RNA and bulk RNA sequencing data to identify prognostic genes associated with pyrimidine metabolism in triple-negative breast cancer by machine learning algorithm combinations. PubMed 42060238
- J Control Release, 2026 (senior author): Augmenting cuproptosis and anti-metastatic immunity in breast cancer by copper-based nanoplatform for synergistic immunotherapy via lactate metabolic reprogramming and hypoxia alleviation. PubMed 41679436
- Front Endocrinol (Lausanne), 2025 (senior author): Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. PubMed 41427052
- Food Sci Nutr, 2025 (senior author): Mendelian Randomization Assessment of the Genetic Effects of Lipid-Lowering Drugs on Digestive System Cancers. PubMed 40443776
- NPJ Precis Oncol, 2024 (senior author): Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. PubMed 39237596
- Onco Targets Ther, 2021 (senior author): Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review. PubMed 34916808
- Mol Ther Nucleic Acids, 2020 (senior author): lncRNA LCPAT1 Upregulation Promotes Breast Cancer Progression via Enhancing MFAP2 Transcription. PubMed 32791452
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion